Genecast (China)

Genecast (also known as Zhenhe Biology / 臻和生物) is a Chinese innovative oncology molecular diagnostics and testing company headquartered in Beijing. Founded in November 2014, the company focuses on non-invasive tumor precision diagnosis and treatment, companion diagnostics, and early cancer screening using next-generation sequencing (NGS) and bioinformatics. Its technology platforms cover three core application scenarios: medication guidance, prognosis prediction, and early screening. Key platforms include ctDNA detection for DNA mutation sequencing, MRD (minimal residual disease) monitoring via its MinerVa platform, RNA extraction and sequencing, DNA methylation sequencing via THEMIS, and mIHC/digital pathology for tumor microenvironment analysis. Genecast offers a comprehensive portfolio of products and services spanning the full cancer care cycle, including early detection and screening for over 20 cancer types, treatment selection, prognosis prediction, and recurrence monitoring. Notable products include Baishibo (百适博), Paidiwan (派蒂万), Langshibo (朗适博), Changshibo (畅适博), Langdisi (朗蒂思), Rongshibo (容适博), Langweibo (朗微博), Rushibo (汝适博), Changweibo (畅微博), Weishibo (微适博), Yishibo (益适博), Zhenbeian (臻倍安), and the MammaPrint (玛普润) breast cancer recurrence test. The company also provides one-stop hospital solutions including automated sample processing systems, integrated bioinformatics analysis machines, and gene sequencing library preparation instruments. Genecast has established a strong research and clinical collaboration network. It operates a precision medicine laboratory in Wuxi, which received CAP accreditation in October 2018 and ISO15189 accreditation in June 2022. The company was recognized as a National High-Tech Enterprise in December 2017. It has formed strategic partnerships with Agendia (2018), PerkinElmer (2020), and Zhejiang University (2020), and in 2021 acquired the global rights and patents for Tissue of Origin. Genecast continues to advance MRD detection and early cancer screening, positioning itself as a leader in tumor liquid biopsy in China.

Genecast was founded in November 2014 in Beijing, China, with a focus on non-invasive tumor precision diagnosis and treatment using next-generation sequencing (NGS) and bioinformatics. In February 2015, the company completed a Series A financing round of 26 million RMB. By January 2016, its R&D headquarters was opened in Health Smart Valley, and in March 2016, a medical device and diagnostic reagent base was established in Taizhou. In January 2016, Genecast launched its first product, Baishibo (百适博). In April 2017, the Genecast (Wuxi) Precision Medicine Laboratory was approved for establishment, and in June 2017, the company launched Paidiwan (派蒂万). July 2017 saw the launch of Langshibo (朗适博) and Changshibo (畅适博). In December 2017, Genecast was recognized as a National High-Tech Enterprise. In April 2018, the Wuxi laboratory obtained its Medical Institution Practice License. In September 2018, Genecast partnered with Agendia to launch MammaPrint (玛普润) in China. In October 2018, the Wuxi laboratory received CAP accreditation from the College of American Pathologists. In September 2019, the laboratory was certified to conduct tumor-related gene testing using both conventional ARMS and NGS methods. In November 2019, Langdisi (朗蒂思) was launched. In April 2020, Rongshibo (容适博) was introduced. In November 2020, Genecast entered strategic partnerships with PerkinElmer and Zhejiang University, and launched Langweibo (朗微博). In September 2021, the company acquired the global rights and patents for Tissue of Origin. In November 2021, Rushibo (汝适博) and the Tissue of Origin product were launched. In February 2022, Changweibo (畅微博) was introduced, followed by Weishibo (微适博) in June 2022. Also in June 2022, Genecast obtained ISO15189 accreditation from A2LA. In December 2022, the company formed a strategic partnership with the Tianjin Free Trade Zone International Innovation Personalized Medicine Research Institute. Throughout its history, Genecast has focused on expanding its product portfolio across the cancer care continuum, from early screening to treatment selection, prognosis, and recurrence monitoring. Its Wuxi laboratory has repeatedly passed CAP proficiency testing, including RNA-A 2022 and ctDNA gene mutation high-throughput sequencing tests. The company has also developed patient management platforms and mobile healthcare initiatives. As of 2022, Genecast continues to operate as a private company headquartered in Beijing, with a strong presence in the Chinese oncology diagnostics market.

• Genecast founded

• Completed Series A financing of 26 million RMB

• R&D headquarters opened in Health Smart Valley; launched Baishibo

• Established medical device and diagnostic reagent base in Taizhou

• Genecast (Wuxi) Precision Medicine Laboratory approved for establishment

• Launched Paidiwan

• Launched Langshibo and Changshibo

• Recognized as National High-Tech Enterprise

• Wuxi laboratory obtained Medical Institution Practice License

• Partnered with Agendia to launch MammaPrint

• Wuxi laboratory received CAP accreditation

• Wuxi laboratory certified for tumor-related gene testing (ARMS and NGS)

• Launched Langdisi

• Launched Rongshibo

• Strategic partnership with PerkinElmer; launched Langweibo; strategic partnership with Zhejiang University

• Acquired global rights and patents for Tissue of Origin

• Launched Rushibo and Tissue of Origin

• Launched Changweibo

• Launched Weishibo; obtained A2LA ISO15189 accreditation

• Strategic partnership with Tianjin Free Trade Zone International Innovation Personalized Medicine Research Institute

Leader in tumor liquid biopsy and precision oncology diagnostics in China, offering full-cycle cancer care solutions from early screening to recurrence monitoring.

• Baishibo

  First product launched in January 2016, likely a cancer diagnostic test.

• Paidiwan

  Launched in June 2017.

• Langshibo

  Launched in July 2017.

• Changshibo

  Launched in July 2017.

• Langdisi

  Launched in November 2019.

• Rongshibo

  Launched in April 2020.

• Langweibo

  Launched in November 2020.

• Rushibo

  Launched in November 2021.

• Tissue of Origin

  Acquired global rights and patents in September 2021; launched November 2021.

• Changweibo

  Launched in February 2022.

• Weishibo

  Pan-cancer MRD detection product launched in June 2022.

• MammaPrint

  Breast cancer recurrence test launched in partnership with Agendia in September 2018.

• MinerVa

  MRD detection platform for early tumor prognosis, long-term recurrence monitoring, and treatment efficacy prediction.

• THEMIS

  Multi-cancer early detection platform using 10mL blood to detect methylation, fragmentomics, copy number, and fragment end motifs.

1. 1臻和生物官网首页genecast.com.cn
2. 2关于我们 - 臻和生物genecast.com.cn
3. 3产品与服务 - 臻和生物genecast.com.cn
4. 4新闻中心 - 臻和生物genecast.com.cn
5. 5Genecast (China) - Wikidatawikidata.org